An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

Key facts

Sponsor

Ohio State University

Principal Investigator

Benjamin Kaffenberger, MD

Dermatologist

Intervention

Ixekizumab(biological)

Enrollment

4 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2018

Study locations (1)

• The Ohio State University Dermatology, Gahanna, Ohio, United States

Collaborators

Eli Lilly and Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic pyoderma gangrenosum

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06624670
  A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
  Boehringer Ingelheim
• RECRUITINGPHASE2NCT06563323
  Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
  Oregon Health and Science University

See all trials for Classic pyoderma gangrenosum →